A002620 Stock Overview
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Jeil Pharma Holdings Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,840.00 |
| 52 Week High | ₩16,000.00 |
| 52 Week Low | ₩9,250.00 |
| Beta | 1.29 |
| 1 Month Change | -8.97% |
| 3 Month Change | -11.91% |
| 1 Year Change | -16.18% |
| 3 Year Change | -55.97% |
| 5 Year Change | -60.80% |
| Change since IPO | 364.15% |
Recent News & Updates
Recent updates
Is Jeil Pharma Holdings Inc (KRX:002620) A Smart Choice For Dividend Investors?
Mar 25
These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27What Percentage Of Jeil Pharma Holdings Inc (KRX:002620) Shares Do Insiders Own?
Jan 23
Jeil Pharma Holdings (KRX:002620) Has Compensated Shareholders With A 56% Return On Their Investment
Dec 28Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23Shareholder Returns
| A002620 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -5.3% | -3.0% | -3.0% |
| 1Y | -16.2% | -0.2% | 0.6% |
Return vs Industry: A002620 underperformed the KR Pharmaceuticals industry which returned -0.2% over the past year.
Return vs Market: A002620 underperformed the KR Market which returned 0.6% over the past year.
Price Volatility
| A002620 volatility | |
|---|---|
| A002620 Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A002620 has not had significant price volatility in the past 3 months.
Volatility Over Time: A002620's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 39 | Seung-Soo Han | www.jeilpharm.co.kr |
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives.
Jeil Pharma Holdings Inc Fundamentals Summary
| A002620 fundamental statistics | |
|---|---|
| Market cap | ₩151.98b |
| Earnings (TTM) | -₩16.25b |
| Revenue (TTM) | ₩804.04b |
0.2x
P/S Ratio-9.3x
P/E RatioIs A002620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A002620 income statement (TTM) | |
|---|---|
| Revenue | ₩804.04b |
| Cost of Revenue | ₩589.46b |
| Gross Profit | ₩214.58b |
| Other Expenses | ₩230.83b |
| Earnings | -₩16.25b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06k |
| Gross Margin | 26.69% |
| Net Profit Margin | -2.02% |
| Debt/Equity Ratio | 52.8% |
How did A002620 perform over the long term?
See historical performance and comparison